Brian Gallagher, MD
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 92.4% of the total across 114 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 36 manufacturers, the largest accounting for just 15.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $931 and has fallen 56.0% since, to $410 in 2025.
Across 114 payments — averaging $35.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$644
- Teleflex LLC$459
- Dornier Medtech America, Inc$314
- Astellas Pharma US Inc$275
- Sumitomo Pharma America, Inc.$255
- Johnson & Johnson$194
- plus $2K from 30 others
Across 1 payment — averaging $23,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Urogen Pharma, Inc.$23K
What the payments were for
- Food & beverage$3,74192%
- Education$3098%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 13 | $644 |
| Teleflex LLC | 6 | $459 |
| Dornier Medtech America, Inc | 2 | $314 |
| Astellas Pharma US Inc | 7 | $275 |
| Sumitomo Pharma America, Inc. | 12 | $255 |
| Johnson & Johnson | 6 | $194 |
| Intuitive Surgical | 2 | $184 |
| AbbVie(2 entities) | 8 | $170 |
| Paragon 28, Inc. | 1 | $139 |
| KARL Storz Endoscopy-america | 3 | $122 |
| Merck | 4 | $120 |
| Medtronic | 2 | $117 |
| Neotract Inc. | 2 | $110 |
| Dendreon Pharmaceuticals LLC | 4 | $106 |
| Olympus America Inc. | 4 | $91 |
| Procept Biorobotics Corporation | 3 | $77 |
| Cook Medical LLC | 5 | $71 |
| Myriad Genetic Laboratories, Inc. | 3 | $63 |
| Axonics, Inc. | 3 | $63 |
| Coloplast | 4 | $55 |
| Urogen Pharma, Inc. | 2 | $53 |
| Ferring Pharmaceuticals Inc. | 2 | $50 |
| Bayer | 2 | $41 |
| Novartis | 1 | $35 |
| E.r. Squibb & Sons, L.L.C. | 2 | $33 |
| Conmed Corporation | 1 | $33 |
| Calyxo, Inc. | 1 | $25 |
| 180 Medical, Inc. | 1 | $20 |
| Pfizer | 1 | $19 |
| Amgen | 1 | $18 |
| Vertex | 1 | $17 |
| Travere Therapeutics, Inc. | 1 | $17 |
| Convatec Inc. | 1 | $15 |
| Endo Pharmaceuticals Inc. | 1 | $15 |
| Endo USA, Inc. | 1 | $15 |
| Progenics Pharmaceuticals, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AMS$236
- Dornier MedTech$195
- Da Vinci Surgical System$154
- UroLift System$141
- PSI IMPLANTS$139
- Lithotripters & Accessories$119
- REZUM$117
- ORGOVYX$116
How this compares
$4,050 in reported general payments places this provider in the 65th percentile of 114 urology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 71 | $47,758 |
| Tamsulosin Hcl | 655 | $8,124 |
| Finasteride | 427 | $4,158 |
| Abiraterone Acetate | 14 | $4,095 |
| Oxybutynin Chloride ErOxybutynin Chloride | 189 | $2,146 |
| Trospium Chloride ErTrospium Chloride | 11 | $1,588 |
| Trospium Chloride | 23 | $1,037 |
| Oxybutynin Chloride | 56 | $685 |
| Bicalutamide | 27 | $631 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 33 | $582 |
| Allopurinol | 28 | $436 |
| Tadalafil | 13 | $317 |
| Ciprofloxacin Hcl | 105 | $311 |
| Dutasteride | 12 | $306 |
| NitrofurantoinNitrofurantoin Macrocrystal | 11 | $226 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $275 | $47,75871 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 114 urology providers in Iowa.
Other urology in Clive
- Ryan DornbierClive$55K
- Mark KellermanClive$14K
- Trevor WildClive$10K
- Stephanie Courson PothovenClive$8K
- McCabe KennyClive$5K
- Jacob JippClive$3K
- Vignesh PackiamIowa City$112K
- Annah VollstedtIowa City$66K
- Bradley EricksonIowa City$65K
- Michael OdonnellIowa City$62K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.